Join the Pre-Exposure Prophylaxis group to help and get support from people like you.
Pre-Exposure Prophylaxis News (Page 2)
Related terms: Pre-Exposure Prophylaxis HIV Infection, PrEP, Reducing Risk of HIV Infection
Twice-Yearly Injection 96% Effective in Preventing HIV Infection
THURSDAY, Nov. 28, 2024 – People whose partners have HIV must remember to take antiretroviral pills every single day or risk infection themselves. But researchers have come up with a way to avoid...
Federal Judge Rules That U.S. Military Cannot Reject HIV-Positive Enlistees
FRIDAY, Aug. 23, 2024 – People with HIV can no longer be turned away if they try to enlist in the U.S. military, a federal judge has ruled. The decision, issued this week by U.S. District Judge...
Long-Acting Early Viral Inhibition Described in Context of Long-Acting Injectable Cabotegravir
MONDAY, July 29, 2024 – In a research letter published online July 24 in the New England Journal of Medicine, the authors describe long-acting early viral inhibition (LEVI) among patients with acute...
Twice-Yearly Lenacapavir Prevents HIV Infection in Young Women
FRIDAY, July 26, 2024 – For adolescent girls and young women, lenacapavir every 26 weeks is beneficial for preventing acquired HIV infection, according to a study published online July 24 in the New...
Twice-a-Year Injection Gives Women Full Protection Against HIV, Trial Finds
MONDAY, June 24, 2024 – Just two injections a year of a new HIV drug protected young women in Africa from infection with the sexually transmitted disease, new trial results show. In announcing the...
FDA Approves Apretude (cabotegravir extended-release injectable suspension) for HIV Pre-Exposure Prophylaxis (PrEP)
LONDON--(BUSINESS WIRE) December 20, 2021 --ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi)...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) in...
FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 15, 2018-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada...